The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations

EGFR-mutant lung cancers develop a wide range of potential resistance alterations under therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET amplification ranks among the most common acquired resistance alterations and is currently being investigated as a therapeutic tar...

Full description

Bibliographic Details
Main Authors: Balázs Jóri, Christine Vössing, Judith Pirngruber, Eva Maria Willing, Kathrin Arndt, Markus Falk, Markus Tiemann, Lukas C. Heukamp, Petra Hoffknecht
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Current Oncology
Subjects:
osimertinib
crizotinib
cabozantinib
sequential therapy
resistance
c-MET
Online Access:https://www.mdpi.com/1718-7729/30/10/635

Internet

https://www.mdpi.com/1718-7729/30/10/635

Similar Items